Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 552

1.

Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in-vitro and ex-vivo studies of complex nanoformulation.

Rapalli VK, Singhvi G, Gorantla S, Waghule T, Dubey SK, Saha RN, Hasnain MS, Nayak AK.

J Sep Sci. 2019 Sep 17. doi: 10.1002/jssc.201900538. [Epub ahead of print]

PMID:
31529758
2.

Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.

Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R.

J Dermatolog Treat. 2019 Sep 16:1-19. doi: 10.1080/09546634.2019.1668907. [Epub ahead of print]

PMID:
31522563
3.

Tazarotene Released from Aligned Electrospun Membrane Facilitates Cutaneous Wound Healing by Promoting Angiogenesis.

Zhu Z, Liu Y, Xue Y, Cheng X, Zhao W, Wang J, He R, Wan Q, Pei X.

ACS Appl Mater Interfaces. 2019 Sep 10. doi: 10.1021/acsami.9b13271. [Epub ahead of print]

PMID:
31503444
4.

DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.

Gupta AK, Love RP, Abramovits W, Vincent KD.

Skinmed. 2019 Sep 9;17(3):181-183. eCollection 2019. No abstract available.

PMID:
31496472
6.

Expanded table: some drugs for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 17;61(1574):e96-e103. No abstract available.

PMID:
31381545
7.

Drugs for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 17;61(1574):89-96. No abstract available.

PMID:
31381544
8.

Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy.

Elmowafy E, El-Gogary RI, Ragai MH, Nasr M.

Int J Pharm. 2019 Sep 10;568:118556. doi: 10.1016/j.ijpharm.2019.118556. Epub 2019 Jul 23.

PMID:
31348982
9.

Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study.

Kirsch B, Hoesly PM, Jambusaria A, Heckman MG, Diehl NN, Sluzevich JC.

J Clin Aesthet Dermatol. 2019 May;12(5):40-45. Epub 2019 May 1.

10.

Building a sequence map of the pig pan-genome from multiple de novo assemblies and Hi-C data.

Tian X, Li R, Fu W, Li Y, Wang X, Li M, Du D, Tang Q, Cai Y, Long Y, Zhao Y, Li M, Jiang Y.

Sci China Life Sci. 2019 Jul 8. doi: 10.1007/s11427-019-9551-7. [Epub ahead of print]

PMID:
31290097
12.

Risankizumab (Skyrizi) for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-83. No abstract available.

PMID:
31170118
13.

Prediction of the skin permeability of topical drugs using in silico and in vitro models.

Alonso C, Carrer V, Espinosa S, Zanuy M, Córdoba M, Vidal B, Domínguez M, Godessart N, Coderch L, Pont M.

Eur J Pharm Sci. 2019 Aug 1;136:104945. doi: 10.1016/j.ejps.2019.05.023. Epub 2019 Jun 1.

PMID:
31163216
14.

A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.

Radonjic A, Evans EL.

Dermatol Ther. 2019 Jul;32(4):e12979. doi: 10.1111/dth.12979. Epub 2019 Jun 17. No abstract available.

PMID:
31155813
15.

Photodynamic Therapy Combined with Dermabrasion in Cutaneous Squamous Cell Carcinoma Concomitant with Psoriasis.

Xu H, Li YM, Ma H, Gu WT, Chen ZQ.

Photobiomodul Photomed Laser Surg. 2019 Mar;37(3):191-193. doi: 10.1089/photob.2018.4552.

PMID:
31050945
16.

Quantification and In Silico Toxicity Assessment of Tazarotene and its Impurities for a Quality and Safe Drug Product Development.

Nagulakonda NNM, Ananthula RS, Krishnamurthy T, Rao MRP, Rao GN.

J Chromatogr Sci. 2019 Aug 1;57(7):625-635. doi: 10.1093/chromsci/bmz037.

PMID:
31037297
17.
18.

Review on Characteristics and Analytical Methods of Tazarotene: An Update.

Gaikwad J, Sharma S, Hatware KV.

Crit Rev Anal Chem. 2019 Apr 3:1-7. doi: 10.1080/10408347.2019.1586519. [Epub ahead of print]

PMID:
30942085
19.

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):297-299.

PMID:
30909352
20.

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Kircik LH, Papp KA, Stein Gold L, Harris S, Pharm TL, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

PMID:
30909333

Supplemental Content

Loading ...
Support Center